138 related articles for article (PubMed ID: 23993130)
1. Single daily dose of moxifloxacin versus ofloxacin plus metronidazole as a new treatment approach to uncomplicated pelvic inflammatory disease: a multicentre prospective randomized trial.
Aşicioğlu O; Gungorduk K; Ozdemir A; Ertas IE; Yildirim G; Sanci M; Ark C
Eur J Obstet Gynecol Reprod Biol; 2013 Nov; 171(1):116-21. PubMed ID: 23993130
[TBL] [Abstract][Full Text] [Related]
2. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial.
Ross JD; Cronjé HS; Paszkowski T; Rakoczi I; Vildaite D; Kureishi A; Alefelder M; Arvis P; Reimnitz P;
Sex Transm Infect; 2006 Dec; 82(6):446-51. PubMed ID: 16723364
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study.
Judlin P; Liao Q; Liu Z; Reimnitz P; Hampel B; Arvis P
BJOG; 2010 Nov; 117(12):1475-84. PubMed ID: 20716255
[TBL] [Abstract][Full Text] [Related]
4. A comparison of treatment outcomes for moxifloxacin versus ofloxacin/metronidazole for first-line treatment of uncomplicated non-gonococcal pelvic inflammatory disease.
Boothby M; Page J; Pryor R; Ross JD
Int J STD AIDS; 2010 Mar; 21(3):195-7. PubMed ID: 20215625
[TBL] [Abstract][Full Text] [Related]
5. A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease.
Heystek M; Ross JD;
Int J STD AIDS; 2009 Oct; 20(10):690-5. PubMed ID: 19815913
[TBL] [Abstract][Full Text] [Related]
6. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections.
Solomkin J; Zhao YP; Ma EL; Chen MJ; Hampel B;
Int J Antimicrob Agents; 2009 Nov; 34(5):439-45. PubMed ID: 19692210
[TBL] [Abstract][Full Text] [Related]
7. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
[TBL] [Abstract][Full Text] [Related]
8. Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA Study).
Weiss G; Reimnitz P; Hampel B; Muehlhofer E; Lippert H;
J Chemother; 2009 Apr; 21(2):170-80. PubMed ID: 19423470
[TBL] [Abstract][Full Text] [Related]
9. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
Hermsen ED; Hovde LB; Sprandel KA; Rodvold KA; Rotschafer JC
Antimicrob Agents Chemother; 2005 Feb; 49(2):685-9. PubMed ID: 15673752
[TBL] [Abstract][Full Text] [Related]
10. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectious diseases group trial XV.
Kern WV; Marchetti O; Drgona L; Akan H; Aoun M; Akova M; de Bock R; Paesmans M; Viscoli C; Calandra T
J Clin Oncol; 2013 Mar; 31(9):1149-56. PubMed ID: 23358983
[TBL] [Abstract][Full Text] [Related]
11. Newest approaches to treatment of pelvic inflammatory disease: a review of recent randomized clinical trials.
Haggerty CL; Ness RB
Clin Infect Dis; 2007 Apr; 44(7):953-60. PubMed ID: 17342647
[TBL] [Abstract][Full Text] [Related]
12. Levofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: a preliminary study.
Judlin P; Thiebaugeorges O
Eur J Obstet Gynecol Reprod Biol; 2009 Aug; 145(2):177-9. PubMed ID: 19467767
[TBL] [Abstract][Full Text] [Related]
13. Moxifloxacin five-day therapy versus placebo in acute bacterial rhinosinusitis.
Hadley JA; Mösges R; Desrosiers M; Haverstock D; van Veenhuyzen D; Herman-Gnjidic Z
Laryngoscope; 2010 May; 120(5):1057-62. PubMed ID: 20422704
[TBL] [Abstract][Full Text] [Related]
14. Treatment of mild-to-moderate pelvic inflammatory disease with a short-course azithromycin-based regimen versus ofloxacin plus metronidazole: results of a multicentre, randomised controlled trial.
Dean G; Soni S; Pitt R; Ross J; Sabin C; Whetham J
Sex Transm Infect; 2021 May; 97(3):177-182. PubMed ID: 33188138
[TBL] [Abstract][Full Text] [Related]
15. Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy.
Kang JM; Kim N; Lee DH; Park YS; Kim YR; Kim JS; Jung HC; Song IS
Helicobacter; 2007 Dec; 12(6):623-8. PubMed ID: 18001404
[TBL] [Abstract][Full Text] [Related]
16. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
[TBL] [Abstract][Full Text] [Related]
17. Once-daily ofloxacin otic solution versus neomycin sulfate/polymyxin B sulfate/hydrocortisone otic suspension four times a day: a multicenter, randomized, evaluator-blinded trial to compare the efficacy, safety, and pain relief in pediatric patients with otitis externa.
Schwartz RH
Curr Med Res Opin; 2006 Sep; 22(9):1725-36. PubMed ID: 16968576
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections.
Gyssens IC; Dryden M; Kujath P; Nathwani D; Schaper N; Hampel B; Reimnitz P; Alder J; Arvis P
J Antimicrob Chemother; 2011 Nov; 66(11):2632-42. PubMed ID: 21896561
[TBL] [Abstract][Full Text] [Related]
19. A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial.
Lloyd A; Holman A; Evers T
Curr Med Res Opin; 2008 May; 24(5):1279-84. PubMed ID: 18358083
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial.
Constantinou M; Daniell M; Snibson GR; Vu HT; Taylor HR
Ophthalmology; 2007 Sep; 114(9):1622-9. PubMed ID: 17822972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
